Puma Biotechnology, Inc. (PBYI) EPS Estimated At $-0.72 on May, 9

April 17, 2018 - By Nellie Rakes

During 2017 Q4 the big money sentiment increased to 1.65. That’s change of 0.10, from 2017Q3’s 1.55. 13 investors sold all, 50 reduced holdings as Puma Biotechnology, Inc. ratio increased. 64 rose stakes while 40 funds bought stakes. Funds hold 34.70 million shares thus 2.80% less from 2017Q3’s 35.70 million shares.
Fred Alger Management accumulated 190,935 shs or 0.09% of the stock. Amalgamated Retail Bank invested in 0.01% or 3,910 shs. Glenmede Tru Na accumulated 146 shs. Proshare Advisors Limited Liability Company, a Maryland-based fund reported 24,485 shs. 8,000 were reported by Nj State Employees Deferred Compensation Plan. Huntington Savings Bank holds 0% of its capital in Puma Biotechnology, Inc. (NASDAQ:PBYI) for 100 shs. Virginia Retirement System Et Al stated it has 14,100 shs. Schwab Charles Inv Mngmt reported 140,198 shs. Eventide Asset Management Ltd Liability accumulated 20,000 shs. Bnp Paribas Arbitrage Sa has invested 0% in Puma Biotechnology, Inc. (NASDAQ:PBYI). Global X Mngmt Communication Ltd Llc has 650 shs. 12,688 are owned by Legal General Gru Public Ltd Co. State Of Wisconsin Invest Board owns 28,600 shs. Millennium Mngmt Lc holds 263,204 shs or 0.04% of its capital. Blackrock Inc holds 0.01% or 2.39 million shs.

Puma Biotechnology, Inc. registered $1.40 million net activity with 0 buys and 4 selling transactions since January 22, 2018. On Monday, January 22 AUERBACH ALAN H sold $991,683 worth of Puma Biotechnology, Inc. (NASDAQ:PBYI) or 10,692 shs. Lo Steven had sold 1,858 shs worth $172,515 on Monday, January 22. Shares for $62,117 were sold by EYLER CHARLES R on Monday, January 22.

Investors wait Puma Biotechnology, Inc. (NASDAQ:PBYI)’s quarterly earnings on May, 9., RTT reports. Analysts predict 63.45 % diference or $-0.72 from the $-1.97 EPS from 2017. -57.89 % EPS growth is what analysts predict. $-1.71 EPS was reported for last [previous quarter]. The stock decreased 0.45% or $0.3 during the last trading session, reaching $66.1.Puma Biotechnology, Inc. has volume of 268,805 shares. Since April 17, 2017 PBYI has risen 66.84% and is uptrending. PBYI outperformed by 55.29% the S&P500.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care.The firm is valued at $2.49 billion. The Company’s drug candidates include PB272 ) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)).Currently it has negative earnings. The firm also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.

Puma Biotechnology, Inc. (NASDAQ:PBYI) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.